Q32 Bio Inc
QTTB1.850USD
+0.110+6.32%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
22.57MMarket Cap
LossP/E TTM
More Details of Q32 Bio Inc Company
Q32 Bio Inc. is a clinical-stage biotechnology company. The Company is engaged in developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Its lead programs, focused on the IL-7 / TSLP receptor pathways and complement system, address immune dysregulation to help patients take back control of their lives. Its program for adaptive immunity, bempikibart (ADX-914), is a fully human anti-IL-7Ra antibody that re-regulates adaptive immune function for the treatment of autoimmune diseases. It is being evaluated in two Phase II trials for the treatment of atopic dermatitis and alopecia areata. Its program for innate immunity, ADX-097, is based on a platform enabling tissue-targeted regulation of the complement system without long-term systemic blockade. The Company has completed a first-in-human, Phase I ascending dose clinical study of ADX-097 in healthy volunteers.
Company Info
Ticker SymbolQTTB
Company nameQ32 Bio Inc
IPO dateMar 28, 2018
CEOMs. Jodie Pope Morrison
Number of employees42
Security typeOrdinary Share
Fiscal year-endMar 28
Address830 Winter Street
CityWALTHAM
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code02451
Phone17819990232
Websitehttps://www.q32bio.com/
Ticker SymbolQTTB
IPO dateMar 28, 2018
CEOMs. Jodie Pope Morrison
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Shelia M. Violette, Ph.D.
Dr. Shelia M. Violette, Ph.D.
Chief Scientific Officer, President of Research
Chief Scientific Officer, President of Research
57.16K
-4.97%
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
5.43K
--
Dr. David S. Grayzel, M.D.
Dr. David S. Grayzel, M.D.
Independent Director
Independent Director
--
--
Dr. Bill Lundberg, M.D.
Dr. Bill Lundberg, M.D.
Independent Director
Independent Director
--
--
Ms. Jodie Pope Morrison
Ms. Jodie Pope Morrison
Chief Executive Officer, Director
Chief Executive Officer, Director
--
-100.00%
Mr. Lee H. Kalowski
Mr. Lee H. Kalowski
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Diyong Xu
Mr. Diyong Xu
Independent Director
Independent Director
--
--
Dr. Isaac Manke
Dr. Isaac Manke
Independent Director
Independent Director
--
--
Ms. Mary T. Thistle, CPA
Ms. Mary T. Thistle, CPA
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Shelia M. Violette, Ph.D.
Dr. Shelia M. Violette, Ph.D.
Chief Scientific Officer, President of Research
Chief Scientific Officer, President of Research
57.16K
-4.97%
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
5.43K
--
Dr. David S. Grayzel, M.D.
Dr. David S. Grayzel, M.D.
Independent Director
Independent Director
--
--
Dr. Bill Lundberg, M.D.
Dr. Bill Lundberg, M.D.
Independent Director
Independent Director
--
--
Ms. Jodie Pope Morrison
Ms. Jodie Pope Morrison
Chief Executive Officer, Director
Chief Executive Officer, Director
--
-100.00%
Mr. Lee H. Kalowski
Mr. Lee H. Kalowski
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Revenue Breakdown
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
OrbiMed Advisors, LLC
18.47%
Atlas Venture
17.15%
Abingworth Management Limited
9.04%
Acorn Capital Advisors, LLC
6.59%
Monaco asset management S.A.M.
4.85%
Other
43.90%
Shareholders
Shareholders
Proportion
OrbiMed Advisors, LLC
18.47%
Atlas Venture
17.15%
Abingworth Management Limited
9.04%
Acorn Capital Advisors, LLC
6.59%
Monaco asset management S.A.M.
4.85%
Other
43.90%
Shareholder Types
Shareholders
Proportion
Venture Capital
28.82%
Private Equity
18.47%
Investment Advisor
17.33%
Corporation
5.92%
Hedge Fund
1.98%
Investment Advisor/Hedge Fund
1.76%
Research Firm
1.17%
Individual Investor
0.62%
Other
23.93%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
211
9.72M
79.73%
-4.89M
2025Q1
223
10.26M
84.16%
-4.38M
2024Q4
223
11.35M
93.20%
-1.04M
2024Q3
208
11.60M
102.62%
+2.77M
2024Q2
197
10.02M
90.20%
+1.83M
2024Q1
230
9.37M
85.14%
+7.24M
2023Q4
242
1.68M
52.16%
-377.72K
2023Q3
262
1.62M
50.50%
-460.61K
2023Q2
275
1.63M
50.84%
-543.11K
2023Q1
291
1.72M
53.55%
-518.81K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
OrbiMed Advisors, LLC
2.25M
18.47%
--
--
Mar 31, 2025
Atlas Venture
2.09M
17.15%
--
--
Mar 31, 2025
Abingworth Management Limited
1.10M
9.04%
--
--
Mar 31, 2025
Acorn Capital Advisors, LLC
803.42K
6.59%
--
--
Mar 31, 2025
Monaco asset management S.A.M.
505.45K
4.14%
-69.36K
-12.07%
Mar 31, 2025
ARCH Venture Partners
320.48K
2.63%
--
--
Mar 31, 2025
Pfizer Inc
277.78K
2.28%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
309.21K
2.54%
-7.36K
-2.32%
Mar 31, 2025
Sanofi SA
244.08K
2%
--
--
Mar 31, 2025
Bristol Myers Squibb
200.24K
1.64%
-558.90K
-73.62%
Dec 31, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Mar 20, 2024
Merger
18→1
Mar 20, 2024
Merger
18→1
Mar 20, 2024
Merger
18→1
Mar 20, 2024
Merger
18→1
Date
Type
Ratio
Mar 20, 2024
Merger
18→1
Mar 20, 2024
Merger
18→1
Mar 20, 2024
Merger
18→1
Mar 20, 2024
Merger
18→1
